We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Distribution Alliance for Infectious Disease Tests

By Labmedica staff writers
Posted on 03 Aug 2004
An agreement has been announced that grants DakoCytomation (Glostrup, Denmark) co-exclusive rights to market and sell the infectious disease diagnostic tests based on the nucleic acid detection of LightUp Technologies AB (Huddinge, Sweden).

The parties will work jointly to achieve a strong market penetration and to develop more products based on LightUp's ReSSQ assay technology and DakoCytomation's knowledge of markets and customer contacts. More...
LightUp is a company developing and commercializing innovative technologies for the fast-growing molecular diagnostic segment of the in vitro diagnostics industry. The company's ReSSQ assays provide simpler and more accurate identification and quantification of disease-generating organisms. The LightUp Probe at the heart of the method is designed to work with real-time polymerase chain reaction (PCR) and can be used in many medical applications.

DakoCytomation is a leading cancer diagnostics company in the field of personalized medicine. The company provides systems solutions for clinical laboratories and life science research. Its tests and instruments allow doctors to link diagnostic results to specific therapies and optimize patient care.



Related Links:
LightUp Technologies
DakoCytomation

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.